Msd Sub Merck Company Profile

✉ Email this page to a colleague

MSD SUB MERCK has fourteen approved drugs.

There are seventeen US patents protecting MSD SUB MERCK drugs.

There are five hundred and five patent family members on MSD SUB MERCK drugs in fifty-nine countries and one hundred and fifty-four supplementary protection certificates in twenty countries.

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Msd Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-001	Dec 15, 2015	AP	RX	Yes	Yes	RE44733*PED	⤷ Start Trial			Y	⤷ Start Trial
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET, CHEWABLE;ORAL	203045-001	Dec 21, 2011		RX	Yes	No	7,754,731*PED	⤷ Start Trial			Y	⤷ Start Trial
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-003	Dec 19, 2017		RX	Yes	No	9,308,204	⤷ Start Trial	Y			⤷ Start Trial
Msd Sub Merck	SEGLUROMET	ertugliflozin; metformin hydrochloride	TABLET;ORAL	209806-001	Dec 19, 2017		RX	Yes	No	8,080,580	⤷ Start Trial	Y	Y		⤷ Start Trial
Msd Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-002	Dec 15, 2015	AP	RX	Yes	No		⤷ Start Trial				⤷ Start Trial
Msd Sub Merck	INVANZ	ertapenem sodium	INJECTABLE;INTRAMUSCULAR, INTRAVENOUS	021337-001	Nov 21, 2001	AP	RX	Yes	Yes		⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	7,459,428	⤷ Start Trial
Msd Sub Merck	INTEGRILIN	eptifibatide	INJECTABLE;INJECTION	020718-002	May 18, 1998	5,747,447	⤷ Start Trial
Msd Sub Merck	ZOLINZA	vorinostat	CAPSULE;ORAL	021991-001	Oct 6, 2006	8,067,472	⤷ Start Trial
Msd Sub Merck	JANUMET XR	metformin hydrochloride; sitagliptin phosphate	TABLET, EXTENDED RELEASE;ORAL	202270-001	Feb 2, 2012	6,340,475	⤷ Start Trial
Msd Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-001	Dec 15, 2015	7,265,099	⤷ Start Trial
Msd Sub Merck	BRIDION	sugammadex sodium	SOLUTION;INTRAVENOUS	022225-001	Dec 15, 2015	6,949,527	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2008-09-30
➤ Subscribe	Injection	0.75 mg/mL, 100 mL vial	➤ Subscribe	2009-06-05
➤ Subscribe	Tablets	400 mg	➤ Subscribe	2011-10-12
➤ Subscribe	Extended-release Capsules	50 mg/500 mg and 50 mg/1000 mg	➤ Subscribe	2012-03-16
➤ Subscribe	Tablets	50 mg/500 mg and 50 mg/1000 mg	➤ Subscribe	2010-10-18
➤ Subscribe	Injection	2 mg/mL, 100 mL vial	➤ Subscribe	2008-12-18
➤ Subscribe	Injection	1 g/vial	➤ Subscribe	2013-06-20
➤ Subscribe	Ophthalmic Solution	2%	➤ Subscribe	2005-10-11
➤ Subscribe	Extended-release Tablets	100 mg/1000 mg	➤ Subscribe	2012-10-22

Subscribe to access the full database, or Start Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1441735	08C0026	France	⤷ Start Trial	PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
2410844	CA 2016 00069	Denmark	⤷ Start Trial	PRODUCT NAME: ELBASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REG. NO/DATE: EU/1/16/1119 20160726
1441735	DO 67; 3-2008	Slovakia	⤷ Start Trial	PRODUCT NAME: RALTEGRAVIR; REGISTRATION NO/DATE: Registration in Community EU/1/07/436/001-002 20071220; FORMER OWNER: ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA. IT
2410844	C02410844/01	Switzerland	⤷ Start Trial	FUSION; FORMER OWNER: MERCK SHARP AND DOHME CORP., US
2410844	16C1026	France	⤷ Start Trial	PRODUCT NAME: ELBASVIR OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/16/1119 20160726
1441735	C 2008 008	Romania	⤷ Start Trial	PRODUCT NAME: N-(2-(4-(4-FLUOROBENZILCARBAMOIL)-5-HIDROXI-1-METIL-6-OXO-1,6-DIHIDROPIRIMIDIN-2-IL)PROPAN-2+IL)-5-METIL-1,3,4-OXADIAZOL-2-CARBOXAMIDA - RALTEGRAVIR SAU O SARE ACCEPTABILAFARMACEUTIC A ACESTUIA, INSPECIAL SAREA DE POTASIU; NATIONAL AUTHORISATION NUMBER: EMEA EU/1/07/436/001, EMEA EU/1/07/436/002; DATE OF NATIONAL AUTHORISATION: 20071220; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EMEA EU/1/07/436/001, EMEA EU/1/07/436/002; DATE OF FIRST AUTHORISATION IN EEA: 20071220
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.